Cargando…

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer

Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Collery, Philippe, Mohsen, Ahmed, Kermagoret, Anthony, Corre, Samantha, Bastian, Gérard, Tomas, Alain, Wei, Ming, Santoni, François, Guerra, Nadia, Desmaële, Didier, d’Angelo, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491361/
https://www.ncbi.nlm.nih.gov/pubmed/26108551
http://dx.doi.org/10.1007/s10637-015-0265-z
_version_ 1782379628692766720
author Collery, Philippe
Mohsen, Ahmed
Kermagoret, Anthony
Corre, Samantha
Bastian, Gérard
Tomas, Alain
Wei, Ming
Santoni, François
Guerra, Nadia
Desmaële, Didier
d’Angelo, Jean
author_facet Collery, Philippe
Mohsen, Ahmed
Kermagoret, Anthony
Corre, Samantha
Bastian, Gérard
Tomas, Alain
Wei, Ming
Santoni, François
Guerra, Nadia
Desmaële, Didier
d’Angelo, Jean
author_sort Collery, Philippe
collection PubMed
description Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. The Re-diselenoether showed a potent inhibitory effect on MDA-MB231 cell division in vitro, which lasted when the complex was no longer present in the culture. Re-diselenoether induced a remarkable reduction of the volume of the primitive breast tumors and of the pulmonary metastases without clinical signs of toxicity, in mice-bearing a MDA-MB231 Luc+ tumor, orthotopically transplanted, after a daily oral administration at the dose of 10 mg/kg/d. Interestingly, an antagonism was observed when cisplatin was administered as a single i.p. injection 1 week after the end of the Re-diselenoether administration. In an effort to gain insight of the mechanisms of action of Re-diselenoether complex, interaction with 9-methylguanine as a nucleic acid base model was studied. We have shown that Re-diselenoether gave both mono- and bis-guanine Re adducts, the species assumed to be responsible for the DNA intrastrand lesions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-015-0265-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4491361
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-44913612015-07-08 Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer Collery, Philippe Mohsen, Ahmed Kermagoret, Anthony Corre, Samantha Bastian, Gérard Tomas, Alain Wei, Ming Santoni, François Guerra, Nadia Desmaële, Didier d’Angelo, Jean Invest New Drugs Preclinical Studies Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. The Re-diselenoether showed a potent inhibitory effect on MDA-MB231 cell division in vitro, which lasted when the complex was no longer present in the culture. Re-diselenoether induced a remarkable reduction of the volume of the primitive breast tumors and of the pulmonary metastases without clinical signs of toxicity, in mice-bearing a MDA-MB231 Luc+ tumor, orthotopically transplanted, after a daily oral administration at the dose of 10 mg/kg/d. Interestingly, an antagonism was observed when cisplatin was administered as a single i.p. injection 1 week after the end of the Re-diselenoether administration. In an effort to gain insight of the mechanisms of action of Re-diselenoether complex, interaction with 9-methylguanine as a nucleic acid base model was studied. We have shown that Re-diselenoether gave both mono- and bis-guanine Re adducts, the species assumed to be responsible for the DNA intrastrand lesions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-015-0265-z) contains supplementary material, which is available to authorized users. Springer US 2015-06-26 2015 /pmc/articles/PMC4491361/ /pubmed/26108551 http://dx.doi.org/10.1007/s10637-015-0265-z Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preclinical Studies
Collery, Philippe
Mohsen, Ahmed
Kermagoret, Anthony
Corre, Samantha
Bastian, Gérard
Tomas, Alain
Wei, Ming
Santoni, François
Guerra, Nadia
Desmaële, Didier
d’Angelo, Jean
Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title_full Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title_fullStr Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title_full_unstemmed Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title_short Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
title_sort antitumor activity of a rhenium (i)-diselenoether complex in experimental models of human breast cancer
topic Preclinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491361/
https://www.ncbi.nlm.nih.gov/pubmed/26108551
http://dx.doi.org/10.1007/s10637-015-0265-z
work_keys_str_mv AT colleryphilippe antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT mohsenahmed antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT kermagoretanthony antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT corresamantha antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT bastiangerard antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT tomasalain antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT weiming antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT santonifrancois antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT guerranadia antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT desmaeledidier antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer
AT dangelojean antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer